Detail akcie PureTech Health online

Business Summary: PureTech Health plc (PureTech) is a biotherapeutics company engaged in the treatment paradigm for devastating diseases. The Company has created a pipeline through its experienced research and development team and its network of scientists, clinicians, and industry leaders. The pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States (U.S.) Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company's wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Puretech Health PLC revenues increased 20% to $7M. Net loss decreased 62% to $28.3M. Revenues reflect Controlled Founded En segment increase of 46% to $4.8M, Parent company & other segment increase from $105K to $328K. Lower net loss reflects Gain/Loss on Derivatives - Hedging increase from $12.5M (expense) to $55.2M (income), Equity Earnings Net of Income Tax decrease of 80% to $15.3M (expense).